Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06467461

Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
University of Minnesota · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

This project will test the hypotheses that people with 5-HT RBD have systemic alpha- synuclein pathology, prodromal DLB signs, and brainstem lesions in regions that control REM sleep. AIM 1 will seek to detect abnormally phosphorylated alpha- synuclein aggregates on targeted skin biopsy in a cohort of people with 5-HT RBD and matched controls (taking SSRIs but without RBD). Aim 2 will use ultra-high field MRI at 7T to examine the pontine region of the coeruleus/subcoeruleus complex for evidence of neurodegeneration as well as segment and parcellate REM sleep related neuronal structures. Aim 3 will test for speech deficits. While these aims are independent we suspect that the severity of autonomic, speech and cognitive deficits will correlate with loss of neuromelanin signal on MRI and pathology on skin biopsy. The investigation is a longitudinal designed study to examine histopathology, neuroimaging changes and speech function from baseline (Time 1) to a follow-up after 30 months (Time 2). A total of 60 individuals, 30 with 5-HT RBD and 30 controls, will be recruited at Time 1, brought back at Time 2, and tested across all Aims at both study visits.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTSkin biopsySkin biopsy to detect systemic alpha-synuclein pathology in 5-HT RBD
DIAGNOSTIC_TESTSpeech testingSpeech Testing to quantify evolving signs of 5-HT RBD
DIAGNOSTIC_TESTUltra high field 7T MRI7T MRI to examine 5-HT RBD for evidence of brainstem neurodegeneration

Timeline

Start date
2024-02-08
Primary completion
2027-12-01
Completion
2028-09-01
First posted
2024-06-21
Last updated
2025-07-08

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06467461. Inclusion in this directory is not an endorsement.